DERM vs SKIN vs PRGO vs AMRX vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 29.

2x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: MCK returned +348. 1% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 4531% more volatile than MCK relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc. grew EPS 157. 9% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amneal Pharmaceuticals, Inc.

(AMRX) is the more profitable company, earning 2. 4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -24. 4% for DERM. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. DERM, SKIN, AMRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +348. 1%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DERM (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare) and AMRX (Healthcare) and MCK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; AMRX is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. PRGO pays a dividend while DERM, SKIN, AMRX, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.